DK1100942T3 - Herpesvirusvektorer til dendristiske celler - Google Patents

Herpesvirusvektorer til dendristiske celler

Info

Publication number
DK1100942T3
DK1100942T3 DK99936848T DK99936848T DK1100942T3 DK 1100942 T3 DK1100942 T3 DK 1100942T3 DK 99936848 T DK99936848 T DK 99936848T DK 99936848 T DK99936848 T DK 99936848T DK 1100942 T3 DK1100942 T3 DK 1100942T3
Authority
DK
Denmark
Prior art keywords
dendritic cells
herpesvirus vectors
herpes virus
cell
virus
Prior art date
Application number
DK99936848T
Other languages
Danish (da)
English (en)
Inventor
Robert Stuart Coffin
Benjamin Chain
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Application granted granted Critical
Publication of DK1100942T3 publication Critical patent/DK1100942T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99936848T 1998-07-31 1999-08-02 Herpesvirusvektorer til dendristiske celler DK1100942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
PCT/GB1999/002529 WO2000008191A2 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Publications (1)

Publication Number Publication Date
DK1100942T3 true DK1100942T3 (da) 2008-02-04

Family

ID=10836553

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99936848T DK1100942T3 (da) 1998-07-31 1999-08-02 Herpesvirusvektorer til dendristiske celler

Country Status (17)

Country Link
US (2) US6641817B1 (enExample)
EP (1) EP1100942B1 (enExample)
JP (1) JP4430824B2 (enExample)
KR (1) KR100635246B1 (enExample)
CN (1) CN1384884B (enExample)
AT (1) ATE374829T1 (enExample)
AU (1) AU765105B2 (enExample)
BR (1) BR9912653A (enExample)
CA (1) CA2337494C (enExample)
CY (1) CY1107844T1 (enExample)
DE (1) DE69937239T2 (enExample)
DK (1) DK1100942T3 (enExample)
ES (1) ES2294848T3 (enExample)
GB (2) GB9816781D0 (enExample)
IL (1) IL141126A0 (enExample)
PT (1) PT1100942E (enExample)
WO (1) WO2000008191A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU2695101A (en) * 2000-01-21 2001-07-31 Biovex Ltd Virus strains
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
EP1406668A1 (en) * 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) * 2007-04-09 2009-01-14 인제대학교 산학협력단 이종 유전자 발현을 위한 숙주균 및 그의 이용방법
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CA2755870C (en) 2009-03-20 2019-04-09 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
AU2011207348A1 (en) 2010-01-21 2012-08-02 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
CA2944903A1 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
HK1248812A1 (zh) 2015-03-06 2018-10-19 Dana-Farber Cancer Institute, Inc. 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
KR20190080825A (ko) 2016-03-21 2019-07-08 다나-파버 캔서 인스티튜트 인크. T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
JP7466308B2 (ja) 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
CA3090305A1 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
EP3768326A1 (en) * 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH Ehv insertion site ul43
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
EP4229222A2 (en) 2020-10-19 2023-08-23 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
US20250381241A1 (en) 2021-11-29 2025-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US20250161413A1 (en) 2022-02-16 2025-05-22 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228008T1 (de) * 1992-07-31 2002-12-15 Harvard College Herpesvirus impfstoffe
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation

Also Published As

Publication number Publication date
HK1037925A1 (en) 2002-02-22
GB2361921B (en) 2003-12-17
PT1100942E (pt) 2007-12-06
DE69937239T2 (de) 2008-07-24
EP1100942A2 (en) 2001-05-23
AU5182299A (en) 2000-02-28
ATE374829T1 (de) 2007-10-15
IL141126A0 (en) 2002-02-10
BR9912653A (pt) 2001-05-02
GB9816781D0 (en) 1998-09-30
EP1100942B1 (en) 2007-10-03
WO2000008191A2 (en) 2000-02-17
US20050249707A1 (en) 2005-11-10
CN1384884B (zh) 2010-12-08
US6641817B1 (en) 2003-11-04
JP2003502008A (ja) 2003-01-21
CA2337494C (en) 2009-06-23
CY1107844T1 (el) 2013-06-19
KR100635246B1 (ko) 2006-10-19
WO2000008191A3 (en) 2000-06-08
CN1384884A (zh) 2002-12-11
JP4430824B2 (ja) 2010-03-10
CA2337494A1 (en) 2000-02-17
ES2294848T3 (es) 2008-04-01
AU765105B2 (en) 2003-09-11
KR20010072162A (ko) 2001-07-31
DE69937239D1 (de) 2007-11-15
GB2361921A (en) 2001-11-07
GB0104400D0 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
DK1100942T3 (da) Herpesvirusvektorer til dendristiske celler
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
ATE224442T1 (de) Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
GB0229032D0 (en) Method of, and system for, heuristically detecting viruses in executable code
ATE306939T1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
ATE215714T1 (de) Anitivirenbeschleuniger
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
MY129773A (en) An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
IL101780A0 (en) Recombinant avipox virus,the culture of cells infected with this virus and vaccines for poultry derived from this virus
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
DK0783585T3 (da) Defekte rekombinante adenovira med et inaktiveret IVa2-gen
PT964697E (pt) Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
ZA914682B (en) Non-a non-b sequences
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
WO1999013064A3 (en) Viral infection of cells using viral vectors
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
DE3779444D1 (de) Impfstoff gegen herpes simplex.
DE59410140D1 (de) Rinderovarzellinie (FROv) zur Virusvermehrung
AU4728299A (en) Antiproliferative and antiviral proteins and peptides
RU93026038A (ru) Способ дифференциации вакцинных и эпизоотических штаммов днк и рнк-содержащих вирусов